Psychiatric diagnoses did not independently predict survival
A retrospective cohort study of 1,269 people with Alzheimer disease found neither psychiatric diagnoses nor recorded psychiatric drug exposure independently predicted survival over a median 112 months.

Our read
Populations- Studied:
- Cohort study of 1,269 patients with Alzheimer disease, median 112 months
- What changed:
- Psychiatric diagnoses did not independently predict death from any cause after accounting for dementia severity, demographic factors, and medical conditions
- The catch:
- Diagnosis codes did not measure the severity of active psychiatric or behavioral symptoms
- In the record:
- The 18th paper on psychotropic medications with results in people; 20 on record in all.
Editor of record: Boris Djordjevic · AgingResearch.News
Among 1,269 patients with specialist-confirmed, clinically diagnosed Alzheimer disease in Taiwan, a retrospective cohort study examined psychiatric diagnoses, recorded medication exposure and long-term survival. Patients received care at a specialist neurology and psychiatry outpatient practice. During a median follow-up of 112 months, 332 patients died.
Psychiatric diagnoses and recorded use of psychiatric medicines were common. Neither independently predicted death from any cause after the researchers accounted for dementia severity, demographic factors and medical conditions. Older age, male sex, kidney failure and cancer were associated with higher mortality. The authors emphasized that these findings did not negate earlier evidence linking active psychiatric and behavioral symptoms or newly started psychiatric medicines with mortality.
Why it matters
For Alzheimer disease, the authors emphasize that assessing survival requires distinguishing active symptoms from formal diagnoses and recorded medication exposure.
Caveats
Diagnosis codes and medication records do not measure the severity of active psychiatric or behavioral symptoms. The findings concern patients receiving specialist outpatient care in Taiwan.
Where the evidence stands
Antidepressants
- 69 independent labs in 33 countries
- 12 findings against
- 6 trials, 5 with no results posted
- Funders: National Institutes of Health and others
- 11 of 96 findings with company ties
Antipsychotics
- 55 independent labs in 23 countries
- 13 findings against
- 5 trials, 2 with no results posted
- Funders: National Institute on Aging and others
- 12 of 73 findings with company ties
The paper
The American Journal of Geriatric Psychiatry, Nov 2026, CC BY-NC-ND


Comments
Be the first to comment.